{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:53:29Z","timestamp":1789872809243,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s11864-017-0495-8","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T01:21:14Z","timestamp":1502328074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Novel Agents in the Treatment of Thymic Malignancies"],"prefix":"10.1007","volume":"18","author":[{"given":"Claire","family":"Merveilleux du Vignaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Maury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"key":"495_CR1","unstructured":"\u2022 WHO histological classification of tumours of the thymus. In: Travis WB, Brambilla A, Burke AP, Marx A, Nicholson A. World Health Organization classification of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2015. This is the standard histopathological classification for thymic tumors."},{"key":"495_CR2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JTO.0000000000000154","volume":"9","author":"A Marx","year":"2014","unstructured":"Marx A, Str\u00f6bel P, Badve SS, et al. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol. 2014;9:596\u2013611.","journal-title":"J Thorac Oncol"},{"key":"495_CR3","doi-asserted-by":"crossref","unstructured":"Girard N. Neuroendocrine tumors of the thymus: the oncologist point of view. J Thorac Dis 2017; in press.","DOI":"10.21037\/jtd.2017.08.18"},{"key":"495_CR4","doi-asserted-by":"crossref","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","volume":"6","author":"F Detterbeck","year":"2011","unstructured":"Detterbeck F, Nicholson AG, Kondo K, et al. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. 2011;6:S1710\u20136.","journal-title":"J Thorac Oncol"},{"key":"495_CR5","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","volume":"9","author":"FC Detterbeck","year":"2014","unstructured":"\u2022 Detterbeck FC, Stratton K, Giroux D, et al. Staging and prognostic factors committee; members of the advisory boards; participating institutions of the thymic domain. The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014;9:S65\u201372. This is the standard staging system for thymic tumors","journal-title":"J Thorac Oncol"},{"issue":"Suppl 5","key":"495_CR6","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"N Girard","year":"2015","unstructured":"\u2022\u2022 Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. ESMO guidelines committee. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v40\u201355. These are the only comprehensive guidelines for thymic tumors","journal-title":"Ann Oncol"},{"key":"495_CR7","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","volume":"6","author":"M Girard","year":"2011","unstructured":"Girard M, Lal R, Wakelee H, et al. Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol. 2011;6:S1749\u201355.","journal-title":"J Thorac Oncol"},{"key":"495_CR8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/CCO.0000000000000355","volume":"29","author":"N Girard","year":"2017","unstructured":"Girard N, Merveilleux du Vignaux C. Systemic treatment for thymic malignancies. Curr Opin Oncol. 2017;29:112\u20137.","journal-title":"Curr Opin Oncol"},{"issue":"9 Suppl 2","key":"495_CR9","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/JTO.0000000000000298","volume":"9","author":"A Rajan","year":"2014","unstructured":"\u2022 Rajan A, Girard N, Marx A. State of the art of genetic alterations in thymic epithelial tumors. J Thorac Oncol. 2014;9(9 Suppl 2):S131\u20136. This is a landmark review on the molecular features of thymic tumors","journal-title":"J Thorac Oncol"},{"key":"495_CR10","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","volume":"15","author":"N Girard","year":"2009","unstructured":"Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res. 2009;15:6790\u20139.","journal-title":"Clin Cancer Res"},{"key":"495_CR11","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-10-1689","volume":"17","author":"M Breinig","year":"2011","unstructured":"Breinig M, Mayer P, Harjung A, et al. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin Cancer Res. 2011;17:2237\u201349.","journal-title":"Clin Cancer Res"},{"key":"495_CR12","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/labinvest.2012.115","volume":"92","author":"Y G\u00f6kmen-Polar","year":"2012","unstructured":"G\u00f6kmen-Polar Y, Sanders KL, Goswami CP, et al. Establishment and characterization of a novel cell line derived from human thymoma AB tumor. Lab Investig. 2012;92:1564\u201373.","journal-title":"Lab Investig"},{"key":"495_CR13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","volume":"11","author":"AT Alberobello","year":"2016","unstructured":"Alberobello AT, Wang Y, Beerkens FJ, et al. PI3K as a potential therapeutic target in thymic epithelial tumors. J Thorac Oncol. 2016;11:1345\u201356.","journal-title":"J Thorac Oncol"},{"key":"495_CR14","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jtho.2016.06.007","volume":"11","author":"N Girard","year":"2016","unstructured":"Girard N. Chasing therapeutic targets in thymic malignancies: finding needles in the haystack to frame a comprehensive canvas? J Thorac Oncol. 2016;11:1197\u2013200.","journal-title":"J Thorac Oncol"},{"key":"495_CR15","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1038\/cddis.2012.92","volume":"3","author":"I Petrini","year":"2012","unstructured":"Petrini I, Meltzer PS, Zucali PA, et al. Copy number aberrations of BCL2 and CDKN2A\/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis. 2012;3:e351.","journal-title":"Cell Death Dis"},{"key":"495_CR16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","volume":"46","author":"I Petrini","year":"2014","unstructured":"Petrini I, Meltzer PS, Kim IK, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 2014;46:844\u20139.","journal-title":"Nat Genet"},{"key":"495_CR17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.lungcan.2015.06.014","volume":"89","author":"M Kossai","year":"2015","unstructured":"Kossai M, Duchemann B, Boutros C, et al. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (phase I trials) at Gustave Roussy. Lung Cancer. 2015;89:306\u201310.","journal-title":"Lung Cancer"},{"key":"495_CR18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.18632\/oncotarget.1015","volume":"4","author":"J Wheler","year":"2013","unstructured":"Wheler J, Hong D, Swisher SG, et al. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 2013;4:890\u20138.","journal-title":"Oncotarget"},{"key":"495_CR19","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1200\/jco.2014.32.15_suppl.7527","volume":"32","author":"PA Zucali","year":"2014","unstructured":"Zucali PA, De Pas TM, Palmieri G, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol. 2014;32:7527. (abstract)","journal-title":"J Clin Oncol"},{"key":"495_CR20","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","volume":"4","author":"G Giaccone","year":"2009","unstructured":"Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol. 2009;4:1270\u20133.","journal-title":"J Thorac Oncol"},{"key":"495_CR21","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1200\/jco.2008.26.15_suppl.8116","volume":"26","author":"JT Salter","year":"2008","unstructured":"Salter JT, Lewis D, Yiannoutsos C, Loehrer PJ, Risley L, Chiorean EG. Imatinib for the treatment of thymic carcinoma. J Clin Oncol. 2008;26:8116. (abstract)","journal-title":"J Clin Oncol"},{"key":"495_CR22","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","volume":"94","author":"G Palmieri","year":"2002","unstructured":"Palmieri G, Montella L, Martignetti A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer. 2002;94:1414\u201320.","journal-title":"Cancer"},{"key":"495_CR23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","volume":"22","author":"PJ Loehrer Sr","year":"2004","unstructured":"Loehrer PJ Sr, Wang W, Johnson DH, et al. Eastern Cooperative Oncology Group Phase II Trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004;22:293\u20139.","journal-title":"J Clin Oncol"},{"key":"495_CR24","doi-asserted-by":"crossref","unstructured":"Ottaviano M, Damiano V, Nappi L, et al. Effectiveness of somatostatin analogs plus prednisone in aggressive histotype and advanced stage of thymic epithelial tumors. J Clin Oncol 2015; 7532 (abstract).","DOI":"10.1093\/annonc\/mdv343.21"},{"key":"495_CR25","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1200\/jco.2014.32.15_suppl.7526","volume":"32","author":"B Besse","year":"2014","unstructured":"Besse B, Garassino MB, Rajan A, et al. A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). J Clin Oncol. 2014;32:7526. (abstract)","journal-title":"J Clin Oncol"},{"key":"495_CR26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","volume":"15","author":"A Rajan","year":"2014","unstructured":"Rajan A, Carter CA, Berman A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15:191\u2013200.","journal-title":"Lancet Oncol"},{"key":"495_CR27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/pr.109.002469","volume":"62","author":"TJ Smith","year":"2010","unstructured":"Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010;62:199\u2013236.","journal-title":"Pharmacol Rev"},{"key":"495_CR28","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","volume":"29","author":"G Giaccone","year":"2011","unstructured":"Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011;29:2052\u20139.","journal-title":"J Clin Oncol"},{"key":"495_CR29","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","volume":"20","author":"A Thomas","year":"2014","unstructured":"Thomas A, Rajan A, Szabo E, et al. A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clin Cancer Res. 2014;20:5392\u2013402.","journal-title":"Clin Cancer Res"},{"key":"495_CR30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","volume":"190","author":"AM Cimpean","year":"2008","unstructured":"Cimpean AM, Raica M, Encica S, Cornea R, Bocan V. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat. 2008;190:238\u201345.","journal-title":"Ann Anat"},{"key":"495_CR31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.thorsurg.2010.08.014","volume":"21","author":"M Marino","year":"2011","unstructured":"Marino M, Piantelli M. Immunohistochemistry of thymic epithelial tumors as a tool in translational research. J Thorac Surg Clin. 2011;21:33\u201346.","journal-title":"J Thorac Surg Clin"},{"key":"495_CR32","doi-asserted-by":"crossref","first-page":"19305","DOI":"10.18632\/oncotarget.4191","volume":"6","author":"R Berardi","year":"2015","unstructured":"Berardi R, Brunelli A, Pagliaretta S, et al. Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy. Oncotarget. 2015;6:19305\u201315.","journal-title":"Oncotarget"},{"key":"495_CR33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","volume":"16","author":"A Thomas","year":"2015","unstructured":"\u2022\u2022 Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16:177\u201386. This is a landmark trial for antiangiogenics as standard treatment of refractory thymic tumors","journal-title":"Lancet Oncol"},{"key":"495_CR34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","volume":"97","author":"J Remon","year":"2016","unstructured":"Remon J, Girard N, Mazieres J, et al. Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network. Lung Cancer. 2016;97:99\u2013104.","journal-title":"Lung Cancer"},{"key":"495_CR35","unstructured":"Besse B, Girard N, Gazzah A, Hierro C, Tabernero J, Debraud F, et al. Clinical activity of lucitanib in advanced thymic epithelial tumors. J Thorac Oncol 2015; 10: MINI 25.07 (abstract)."},{"key":"495_CR36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2017.05.008","volume":"110","author":"N Girard","year":"2017","unstructured":"Girard N. Thymic malignancies: twisting between autoimmunity and immunotherapy. Lung Cancer. 2017;110:68\u201370.","journal-title":"Lung Cancer"},{"key":"495_CR37","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1084\/jem.191.5.891","volume":"191","author":"H Nishimura","year":"2000","unstructured":"Nishimura H, Honjo T, Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med. 2000;191:891\u20138.","journal-title":"J Exp Med"},{"key":"495_CR38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","volume":"88","author":"Y Katsuya","year":"2015","unstructured":"Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015;88:154\u20139.","journal-title":"Lung Cancer"},{"key":"495_CR39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","volume":"10","author":"SK Padda","year":"2015","unstructured":"Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015;10:500\u20138.","journal-title":"J Thorac Oncol"},{"key":"495_CR40","doi-asserted-by":"crossref","unstructured":"Naidoo J, Steele K, Sima CS, Yuan J, Robbins PB, Moreira AL, et al. Defining the immunological phenotype of thymic epithelial tumors. J Clin Oncol. 2015;33(suppl; abstr):7516.","DOI":"10.1200\/jco.2015.33.15_suppl.7516"},{"key":"495_CR41","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","volume":"101","author":"S Yokoyama","year":"2016","unstructured":"Yokoyama S, Miyoshi H, Nishi T, Hashiguchi T, Mitsuoka M, Takamori S, et al. Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma. Ann Thorac Surg. 2016;101:1361\u20139.","journal-title":"Ann Thorac Surg"},{"key":"495_CR42","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1158\/1078-0432.CCR-16-0434","volume":"22","author":"S Yokoyama","year":"2016","unstructured":"Yokoyama S, Miyoshi H, Nakashima K, Shimono J, Hashiguchi T, Mitsuoka M, et al. Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma. Clin Cancer Res. 2016;22:4727\u201334.","journal-title":"Clin Cancer Res"},{"key":"495_CR43","doi-asserted-by":"publisher","unstructured":"Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Bassett R, Wistuba II, et al. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017; doi: 10.1038\/modpathol.2017.6 .","DOI":"10.1038\/modpathol.2017.6"},{"key":"495_CR44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","volume":"60","author":"AM Marchevsky","year":"2017","unstructured":"Marchevsky AM, Walts AE. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus. Hum Pathol. 2017;60:16\u201323.","journal-title":"Hum Pathol"},{"key":"495_CR45","doi-asserted-by":"crossref","first-page":"E535","DOI":"10.21037\/jtd.2016.06.32","volume":"8","author":"Y Yang","year":"2016","unstructured":"Yang Y, Ding L, Wang P. Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases. J Thorac Dis. 2016;8:E535\u20137.","journal-title":"J Thorac Dis"},{"key":"495_CR46","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jtho.2016.07.018","volume":"11","author":"T Zander","year":"2016","unstructured":"Zander T, Aebi S, Rast AC, Zander A, Winterhalder R, Brand C, et al. Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases. J Thorac Oncol. 2016;11:e147\u20139.","journal-title":"J Thorac Oncol"},{"key":"495_CR47","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Giaccone G, Thompson J, Crawford J, et al. A phase II study of pembrolizumab in patients with recurrent thymic carcinoma. J Clin Oncol. 2016; 34: suppl; 8517. Abstr. This is a landmark trial with immunootherapy for thymic carcinoma.","DOI":"10.1200\/JCO.2016.34.15_suppl.8517"},{"key":"495_CR48","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jtho.2016.11.117","volume":"12","author":"A Rajan","year":"2017","unstructured":"Rajan A, Heery CR, Mammen AL, Pittaluga S, Lepone ML, Donahue RN, et al. OA18.03: safety and clinical activity of avelumab (MSB0010718C; anti-PD-L1) in patients with advanced thymic epithelial tumors (TETs). J Thorac Oncol. 2017;12:S130.","journal-title":"J Thorac Oncol"},{"key":"495_CR49","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2017.35.15_suppl.8521","volume":"35","author":"J Cho","year":"2017","unstructured":"Cho J, Ahn MJ, Yoo KH, et al. A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor. J Clin Oncol. 2017;35:8521. (abstract)","journal-title":"J Clin Oncol"},{"key":"495_CR50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.lungcan.2016.09.015","volume":"101","author":"A Thomas","year":"2016","unstructured":"Thomas A, Chen Y, Berman A, et al. Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. Lung Cancer. 2016;101:104\u201310.","journal-title":"Lung Cancer"},{"key":"495_CR51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2014.05.010","volume":"85","author":"R Lattanzio","year":"2014","unstructured":"Lattanzio R, La Sorda R, Facciolo F, et al. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue microarray-based multicenter study. Lung Cancer. 2014;85:191\u20136.","journal-title":"Lung Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-017-0495-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-017-0495-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-017-0495-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T06:35:27Z","timestamp":1569998127000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-017-0495-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["495"],"URL":"https:\/\/doi.org\/10.1007\/s11864-017-0495-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]},"article-number":"52"}}